SCHEMBL25754665

SCHEMBL25754665

CC#CCCOCCCNCCN1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
KDM1A O60341 1/20 0.36
ACE2 Q9BYF1 1/20 0.35
HRH3 Q9Y5N1 7/20 0.35
SIGMAR1 Q99720 3/20 0.34
SCN5A Q14524 3/20 0.33
SLC6A2 P23975 2/20 0.33
HRH1 P35367 2/20 0.33
CHRM2 P08172 1/20 0.33
ADRA2C P18825 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
KCNH2 Q12809 1/20 0.33
CACNA1C Q13936 1/20 0.33
CHRM4 P08173 1/20 0.33
HTR2C P28335 1/20 0.33
HTR7 P34969 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754680 0.94 CARM1 (0.36) CARM1PRMT6PRMT8KDM1AACE2
SCHEMBL25754658 0.91 CARM1 (0.38) CARM1PRMT6PRMT8KDM1AACE2
SCHEMBL25754671 0.89 HRH3 (0.38) CARM1PRMT6PRMT8HRH3SIGMAR1
SCHEMBL25754677 0.89 HRH3 (0.38) CARM1PRMT6PRMT8HRH3SIGMAR1
SCHEMBL25754652 0.85 CARM1 (0.42) CARM1PRMT6PRMT8KDM1AACE2
SCHEMBL25754685 0.84 HRH3 (0.40) HRH3SIGMAR1SCN5ASLC6A2HRH1
SCHEMBL25754661 0.83 HRH3 (0.40) HRH3SIGMAR1SCN5ASLC6A2HRH1
SCHEMBL25754576 0.82 HRH3 (0.48) HRH3KCNH2
SCHEMBL25754584 0.82 HRH3 (0.48) HRH3KCNH2
SCHEMBL25754568 0.79 HRH3 (0.43) HRH3SIGMAR1SCN5ASLC6A2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 CARM1 1753/4885PRMT6 1350/4885PRMT8 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.